Online inquiry

IVTScrip™ mRNA-Human APMAP, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WK24913MR)

This product GTTS-WK24913MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the APMAP protein. This product can be used in CD4+ cytotoxic T cell-related researches.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Human
RefSeq NM_020531.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification Chromatography
Target Gene
Gene ID 57136
UniProt ID Q9HDC9
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Human APMAP, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WK24913MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WK22196MR IVTScrip™ mRNA-Human ATP5C1, (Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ATP5C1
GTTS-WK26695MR IVTScrip™ mRNA-Human ATP5B, (Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ATP5B
GTTS-WK19567MR IVTScrip™ mRNA-Human AKD1, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AKD1
GTTS-WK4415MR IVTScrip™ mRNA-Human PKC-alpha, (Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PKC-alpha
GTTS-WK18465MR IVTScrip™ mRNA-Human AMZ2, (Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMZ2
GTTS-WK0380MR IVTScrip™ mRNA-Human CD156b, (Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CD156b
GTTS-WK7054MR IVTScrip™ mRNA-Human MMP9, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MMP9
GTTS-WK21438MR IVTScrip™ mRNA-Human ALPI, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ALPI
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW